Andrew Spencer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9615898/publications.pdf

Version: 2024-02-01

211 papers	13,209 citations	81900 39 h-index	23533 111 g-index
213 all docs	213 docs citations	213 times ranked	10667 citing authors

#	Article	IF	Citations
1	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood, 2022, 139, 835-844.	1.4	43
2	A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy. Critical Reviews in Oncology/Hematology, 2022, 172, 103606.	4.4	6
3	Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with Î²-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo. Cancers, 2022, 14, 840.	3.7	7
4	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. Frontiers in Oncology, 2022, 12, 820768.	2.8	5
5	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2022, 107, 774-775.	3.5	2
6	The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma. Bone Marrow Transplantation, 2022, 57, 1001-1003.	2.4	1
7	Carfilzomib 56â€‰mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. Leukemia and Lymphoma, 2022, 63, 1887-1896.	1.3	3
8	MÄori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	0
9	The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. Bone Marrow Transplantation, 2022, 57, 982-989.	2.4	3
10	Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning. Bone Marrow Transplantation, 2022, , .	2.4	0
11	Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy.. Journal of Clinical Oncology, 2022, 40, 8037-8037.	1.6	0
12	Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.. Journal of Clinical Oncology, 2022, 40, 8052-8052.	1.6	4
13	Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia, 2021, 35, 255-258.	7.2	48
14	TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Leukemia and Lymphoma, 2021, 62, 337-347.	1.3	2
15	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	7.2	69
16	Important factors in implementation of lineage-specific chimerism analysis for routine use. Bone Marrow Transplantation, 2021, 56, 946-948.	2.4	3
17	Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML). Leukemia and Lymphoma, 2021, 62, 489-491.	1.3	0
18	Treatment of invasive IMPâ€4Enterobacter cloacaeinfection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review. Transplant Infectious Disease, 2021, 23, e13510.	1.7	20

#	Article	IF	Citations
19	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	10.7	46
20	Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma. Bone Marrow Transplantation, 2021, 56, 1116-1125.	2.4	2
21	Phase II trial of singleâ€agent panobinostat consolidation improves responses after subâ€optimal transplant outcomes in multiple myeloma. British Journal of Haematology, 2021, 193, 160-170.	2.5	4
22	Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma. Methods in Molecular Biology, 2021, 2261, 151-191.	0.9	8
23	Healthâ€related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British Journal of Haematology, 2021, 193, 561-569.	2.5	10
24	Human myeloma cellâ€and plasmaâ€derived extracellular vesicles contribute to functional regulation of stromal cells. Proteomics, 2021, 21, e2000119.	2.2	13
25	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Journal of Clinical Oncology, 2021, 39, 1139-1149.	1.6	57
26	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 2021, 56, 2533-2543.	2.4	7
27	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16â€02 trial. British Journal of Haematology, 2021, 194, 580-586.	2.5	5
28	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. British Journal of Haematology, 2021, 194, 120-131.	2.5	27
29	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplantâ€ineligible patients with myeloma who are treated with bortezomibâ€based induction. European Journal of Haematology, 2021, 107, 497-499.	2.2	2
30	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 752-765.	0.4	10
31	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e510-e520.	0.4	12
32	Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders. Leukemia, 2021, 35, 2771-2783.	7.2	17
33	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leukemia and Lymphoma, 2021, 62, 2981-2991.	1.3	2
34	Australia and New Zealand Transplant and Cellular Therapies <scp>COVIDâ€19</scp> vaccination consensus position statement. Internal Medicine Journal, 2021, 51, 1321-1323.	0.8	6
35	Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma. Frontiers in Oncology, 2021, 11, 718502.	2.8	4
36	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	1.6	25

#	Article	IF	Citations
37	Planned withdrawal of dexamethasone after pomalidomide low dose dexamethasone induction for lenalidomide refractory multiple myeloma (ALLG MM14). Haematologica, 2021, , .	3.5	0
38	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.8	1
39	Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood, 2021, 138, 4757-4757.	1.4	0
40	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2021, 138, 2728-2728.	1.4	1
41	Targeting Bclxl Mitigates Mcl1 Chemoresistance in Multiple Myeloma. Blood, 2021, 138, 2656-2656.	1.4	0
42	The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma. Cells, 2021, 10, 3464.	4.1	11
43	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica, 2020, 105, 468-477.	3.5	41
44	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 509-518.	0.4	91
45	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. Biology of Blood and Marrow Transplantation, 2020, 26, 2252-2261.	2.0	6
46	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of Hematology and Oncology, 2020, 13, 115.	17.0	32
47	High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission. Bone Marrow Transplantation, 2020, 55, 2207-2210.	2.4	0
48	Bone Marrow Transplant Society of Australia and New Zealand COVIDâ€19 consensus position statement. Internal Medicine Journal, 2020, 50, 774-775.	0.8	3
49	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology, 2020, 99, 1793-1804.	1.8	4
50	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
51	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia, 2020, 34, 1840-1852.	7.2	55
52	Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews, 2020, 44, 100672.	5.7	135
53	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	6.2	75
54	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€“melphalanâ€“prednisone, with or without bortezomibâ€“lenalidomideâ€“dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology,the, 2020, 7, e456-e468.	4.6	244

#	Article	IF	Citations
55	Patientâ€reported outcome measures in multiple myeloma: Realâ€time reporting to improve care (<scp>Myâ€PROMPT</scp>) â€•a pilot randomized controlled trial. American Journal of Hematology, 2020, 95, E178-E181.	4.1	6
56	Brick plots: an intuitive platform for visualizing multiparametric immunophenotyped cell clusters. BMC Bioinformatics, 2020, 21, 145.	2.6	4
57	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTEÂ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). Blood, 2020, 136, 28-29.	1.4	83
58	Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 26-27.	1.4	40
59	Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 14-15.	1.4	7
60	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 42-43.	1.4	58
61	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2020, 136, 4-5.	1.4	1
62	An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation. Blood, 2020, 136, 36-37.	1.4	1
63	Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison. Blood, 2020, 136, 8-9.	1.4	1
64	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 11-12.	1.4	2
65	Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 18-19.	1.4	0
66	Peripheral Blood CD34+ Donor Chimerism Is Superior to CD3+ Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Blood, 2020, 136, 47-48.	1.4	0
67	Malignant Clonal Cell Proliferation in Multiple Myeloma and the Hypercoagulable State. Blood, 2020, 136, 23-24.	1.4	0
68	The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood, 2020, 136, 30-31.	1.4	2
69	Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial). Blood, 2020, 136, 34-35.	1.4	0
70	Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor. Blood, 2020, 136, 38-41.	1.4	0
71	DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients. Cancers, 2019, 11, 917.	3.7	16
72	Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients. Cancers, 2019, 11, 887.	3.7	20

#	Article	IF	Citations
73	Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e470-e477.	0.4	3
74	Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leukemia and Lymphoma, 2019, 60, 2143-2151.	1.3	13
75	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e415-e424.	0.4	13
76	Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia, 2019, 33, 2022-2033.	7.2	49
77	Panobinostat (LBH589) in combination with the Î²-catenin inhibitor Tegavivint (BC2059) exerts significant anti-myeloma activity both in vitro and in vivo. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e137.	0.4	1
78	Phase 2 study of allâ€oral ixazomib, cyclophosphamide and lowâ€dose dexamethasone for relapsed/refractory multiple myeloma. British Journal of Haematology, 2019, 184, 536-546.	2.5	16
79	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
80	Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC) Tj ETQq0 0 1 rgBT /Overlock 10	1.4	1
81	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. Blood, 2019, 134, 142-142.	1.4	25
82	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. Journal of Clinical Oncology, 2019, 37, 8040-8040.	1.6	1
83	DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2842-2846.	1.3	12
84	Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. Haematologica, 2018, 103, e25-e28.	3.5	19
85	Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomes. Supportive Care in Cancer, 2018, 26, 947-955.	2.2	6
86	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica, 2018, 103, 2079-2087.	3.5	225
87	Analysis of Circulating Tumor DNA. Methods in Molecular Biology, 2018, 1792, 129-145.	0.9	10
88	Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma. International Journal of Molecular Sciences, 2018, 19, 1858.	4.1	28
89	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
90	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 2018, 132, 301-301.	1.4	9

#	Article	IF	Citations
91	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor. Blood, 2018, 132, 3272-3272.	1.4	17
92	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. Blood, 2018, 132, 3289-3289.	1.4	4
93	An Evidence-Based Approach to Myeloma Bone Disease. Current Hematologic Malignancy Reports, 2017, 12, 109-118.	2.3	12
94	Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemotherapy and Pharmacology, 2017, 79, 1067-1076.	2.3	21
95	Î²-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. Molecular Cancer Therapeutics, 2017, 16, 1765-1778.	4.1	39
96	Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2017, 215, 1684-1694.	4.0	61
97	Myeloma in the Real World: What Is Really Happening?. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 133-144.e1.	0.4	34
98	Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. Biology of Blood and Marrow Transplantation, 2017, 23, 1961-1967.	2.0	56
99	Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2017, 8, 1506.	4.8	13
100	Safety and efficacy of daratumumab-based regimens in elderly (â‰¥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. Journal of Clinical Oncology, 2017, 35, 8033-8033.	1.6	3
101	Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. Journal of Clinical Oncology, 2017, 35, 8036-8036.	1.6	4
102	The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget, 2017, 8, 52269-52280.	1.8	20
103	Circulating tumour DNA analysis in multiple myeloma. Oncotarget, 2017, 8, 90610-90611.	1.8	7
104	Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biology and Medicine, 2016, 13, 215-225.	3.0	36
105	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer, 2016, 122, 2050-2056.	4.1	40
106	Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. Clinical Cancer Research, 2016, 22, 4559-4566.	7.0	56
107	Myeloma of the central nervous system â€“ an ongoing conundrum!. Leukemia and Lymphoma, 2016, 57, 1505-1506.	1.3	3
108	Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation. Cancer Treatment Reviews, 2016, 50, 200-204.	7.7	8

#	Article	IF	Citations
109	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood, 2016, 128, 1834-1844.	1.4	127
110	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 754-766.	27.0	1,246
111	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
112	Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Medical Research Methodology, 2016, 16, 151.	3.1	25
113	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 27-38.	10.7	723
114	Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. Journal of Antimicrobial Chemotherapy, 2016, 71, 497-505.	3.0	30
115	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. Blood, 2016, 128, 2980-2980.	1.4	3
116	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. Blood, 2016, 128, 3326-3326.	1.4	6
117	A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy. Blood, 2016, 128, 4515-4515.	1.4	1
118	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. Journal of Clinical Oncology, 2016, 34, LBA4-LBA4.	1.6	5
119	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. Journal of Clinical Oncology, 2016, 34, LBA4-LBA4.	1.6	13
120	Overcoming Innate Resistance to a Beta-Catenin Inhibitor-BC2059- By Manipulating Autophagy in Multiple Myeloma. Blood, 2016, 128, 5669-5669.	1.4	0
121	TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma. Blood, 2016, 128, 4461-4461.	1.4	0
122	Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". Haematologica, 2015, 100, e379-e379.	3.5	4
123	A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Haematologica, 2015, 100, e60-e62.	3.5	7
124	Phase 1/1<scp>B</scp> trial of the heat shock protein 90 inhibitor <scp>NVP</scp>â€<scp>AUY</scp>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer, 2015, 121, 2185-2192.	4.1	51
125	Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. Transfusion, 2015, 55, 2709-2713.	1.6	13
126	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2015, 373, 621-631.	27.0	1,139

#	Article	IF	Citations
127	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica, 2015, 100, 1327-1333.	3.5	68
128	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	1.6	1,525
129	The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer, 2015, 51, 1467-1475.	2.8	43
130	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1617-1629.	10.7	289
131	Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide. Blood, 2015, 126, 3033-3033.	1.4	1
132	Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. Blood, 2015, 126, 4220-4220.	1.4	7
133	Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre. Blood, 2015, 126, 5543-5543.	1.4	1
134	Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).. Journal of Clinical Oncology, 2015, 33, TPS8609-TPS8609.	1.6	5
135	The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study. Blood, 2015, 126, 4312-4312.	1.4	0
136	In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma. Blood, 2015, 126, 1816-1816.	1.4	0
137	Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia. Blood, 2015, 126, 2030-2030.	1.4	0
138	Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors. Blood, 2015, 126, 5375-5375.	1.4	0
139	Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics, 2014, 9, 1511-1520.	2.7	140
140	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 333-342.	10.7	256
141	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 587-600.	1.6	330
142	Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia. International Journal of Antimicrobial Agents, 2014, 44, 450-457.	2.5	10
143	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood, 2014, 124, 2190-2195.	1.4	108
144	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 3448-3448.	1.4	1

#	Article	IF	Citations
145	Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments. Blood, 2014, 124, 2103-2103.	1.4	0
146	International Myeloma Working Group Recommendations for the Treatment of Multiple Myelomaâ€“Related Bone Disease. Journal of Clinical Oncology, 2013, 31, 2347-2357.	1.6	307
147	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq1 1 0.784314 rgBT /Ove	10.7	219
148	Histone deacetylase (<scp>HDAC</scp>) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I <scp>HDAC</scp>. British Journal of Haematology, 2013, 162, 559-562.	2.5	33
149	Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. Blood, 2013, 122, 2939-2939.	1.4	2
150	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 408-408.	1.4	10
151	Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.. Journal of Clinical Oncology, 2013, 31, 8589-8589.	1.6	2
152	Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality. Blood, 2013, 122, 2128-2128.	1.4	2
153	BC2059: An Orally Bioavailable Î²-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma. Blood, 2013, 122, 1920-1920.	1.4	0
154	Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival. Blood, 2012, 120, 4065-4065.	1.4	1
155	Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor. Blood, 2012, 120, 1842-1842.	1.4	0
156	CD45-Ve but Not CD45+Ve U266 Myeloma Cells Demonstrate an Active Epithelial to Mesenchymal Transition (EMT) Transcriptional Programme. Blood, 2012, 120, 3988-3988.	1.4	0
157	The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells. Blood, 2012, 120, 4012-4012.	1.4	0
158	Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Journal of Clinical Oncology, 2011, 29, 1125-1132.	1.6	1,090
159	Reply to S.M. Sorscher et al. Journal of Clinical Oncology, 2011, 29, 2736-2737.	1.6	2
160	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study. Blood, 2011, 118, 1529-1529.	1.4	1
161	Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study. Blood, 2011, 118, 1856-1856.	1.4	10
162	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. Blood, 2011, 118, 2599-2599.	1.4	7

#	Article	IF	Citations
163	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood, 2011, 118, 302-302.	1.4	28
164	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. Blood, 2011, 118, 811-811.	1.4	16
165	Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,. Blood, 2011, 118, 3631-3631.	1.4	0
166	A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998â€“2008,. Blood, 2011, 118, 4143-4143.	1.4	0
167	A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,. Blood, 2011, 118, 3625-3625.	1.4	1
168	No longer the poor relations. Blood, 2010, 116, 3685-3686.	1.4	1
169	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. Blood, 2010, 116, 3299-3299.	1.4	6
170	A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood, 2010, 116, 5031-5031.	1.4	10
171	Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study. Blood, 2010, 116, 3301-3301.	1.4	1
172	Reply to M. Cavo. Journal of Clinical Oncology, 2009, 27, e188-e188.	1.6	0
173	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. Journal of Clinical Oncology, 2009, 27, 1788-1793.	1.6	315
174	Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.. Blood, 2009, 114, 1876-1876.	1.4	4
175	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.. Blood, 2009, 114, 2693-2693.	1.4	2
176	Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.. Blood, 2009, 114, 2898-2898.	1.4	7
177	A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).. Blood, 2009, 114, 750-750.	1.4	13
178	MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells.. Blood, 2009, 114, 1846-1846.	1.4	0
179	A Novel Orally Bioavailable Heat Shock Protein 90 Inhibitor Induces Apoptosis and Synergises with Bortezomib in Human Multiple Myeloma.. Blood, 2009, 114, 1838-1838.	1.4	0
180	Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clinical Pharmacology, 2008, 8, 2.	2.5	9

#	Article	IF	Citations
181	Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008, 111, 3968-3977.	1.4	294
182	A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. Blood, 2008, 112, 2774-2774.	1.4	19
183	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. Blood, 2008, 112, 3701-3701.	1.4	3
184	Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. Blood, 2008, 112, 958-958.	1.4	32
185	A Newly Developed IAP Inhibitor (IAPi) Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics. Blood, 2008, 112, 5156-5156.	1.4	0
186	Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.. Blood, 2007, 110, 1510-1510.	1.4	3
187	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Â± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. Blood, 2007, 110, 2735-2735.	1.4	1
188	An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).. Blood, 2007, 110, 3604-3604.	1.4	11
189	Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.. Blood, 2007, 110, 4941-4941.	1.4	2
190	Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.. Blood, 2007, 110, 907-907.	1.4	11
191	Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. Blood, 2007, 110, 2740-2740.	1.4	1
192	A New Generation XIAP Inhibitor Induces Apoptosis of Human Myeloma Cells and Synergises with Conventional and Novel Anti-Myeloma Therapeutics.. Blood, 2007, 110, 4787-4787.	1.4	1
193	Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).. Blood, 2006, 108, 3551-3551.	1.4	13
194	Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.. Blood, 2006, 108, 3554-3554.	1.4	14
195	Laboratory Tumor Lysis Syndrome Complicating LBH589 Therapy in a Patient with Acute Myeloid Leukemia.. Blood, 2006, 108, 4554-4554.	1.4	1
196	First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).. Blood, 2006, 108, 58-58.	1.4	22
197	The Focal Adhesion Kinase (FAK) Inhibitor TAE226 Exhibits In Vitro and In Vivo Activity Against Multiple Myeloma.. Blood, 2006, 108, 844-844.	1.4	0
198	Modulation of the Mitochondrial (Type 2) Apoptotic Pathway Can Enhance Apo2L/TRAIL - Mediated Killing of Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3447-3447.	1.4	0

#	Article	IF	Citations
199	Azacitidine Down-Regulates Both IL-6 Signalling and NFkB Activity in Human Myeloma Cells.. Blood, 2006, 108, 3441-3441.	1.4	13
200	Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.. Blood, 2006, 108, 2450-2450.	1.4	0
201	The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.. Blood, 2005, 106, 5108-5108.	1.4	2
202	Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).. Blood, 2005, 106, 6-6.	1.4	70
203	Azacytidine Suppressors Autocrine IL-6 Secretion and Demonstrates In Vitro and In Vivo Activity Against Multiple Myeloma.. Blood, 2005, 106, 1566-1566.	1.4	0
204	An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.. Blood, 2005, 106, 3336-3336.	1.4	0
205	PKC412 Induces Apoptosis in Human Multiple Myeloma Cell Lines and Primary Myeloma Cells.. Blood, 2005, 106, 1587-1587.	1.4	0
206	Flavopiridol Decreases the Level of p21 and Induces Apoptosis in Human Myeloma Cell Lines.. Blood, 2005, 106, 5188-5188.	1.4	1
207	Gene Expression Profiling in Multiple Myeloma Cells Treated with the Novel Anti-Myeloma Agents Zoledronate and Fluvastatin.. Blood, 2005, 106, 5078-5078.	1.4	0
208	Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. The Hematology Journal, 2004, 5, 216-221.	1.4	10
209	Fluvastatin-Zometa (FluZom) as A Possible Therapeutic Approach to Plasma Cell Disorders.. Blood, 2004, 104, 4937-4937.	1.4	0
210	A Stratified Risk-Adapted Approach to Lymphoma Salvage in an Outpatient Setting.. Blood, 2004, 104, 4597-4597.	1.4	1
211	Tumour Kinetics in Multiple Myeloma Before, During, and After Treatment. Leukemia and Lymphoma, 2001, 40, 373-384.	1.3	5